Filter results by

Guidance and Policy (3625)
Guidance (1676)
Policy and Strategy (1928)
Quality Indicators (1)
Prescribing and Technical Information (1598)
Secondary Evidence (83)
Systematic Reviews (1)
Economic Evaluations (2)
Evidence Summaries (82)
Primary Research (543)
Practice Based Information (6)
Audit and Inspection Reports (6)
Medicines Current Awareness (28)
Implementation Support (6)
Information for the Public (3)

Area of interest

Drugs and Technologies (28)
Public Health (1)

Source

Action on Smoking and Health - ASH (1)
Age UK (2)
All Wales Medicines Strategy Group - AWMSG (17)
Alzheimer's Society (1)
British Association of Dermatologists - BAD (15)
British Heart Foundation (1)
British Thoracic Society - BTS (7)
Care Quality Commission - CQC (4)
Diabetes UK (4)
Digital Health Evaluation Collection (1)
electronic Medicines Compendium - eMC (186)
European Medicines Agency - EMA (56)
GOV UK (2)
Health Foundation (8)
Healthcare Improvement Scotland (66)
Healthcare Quality Improvement Partnership - HQIP (3)
House of Commons (1)
King's Fund (7)
Local Government Association (2)
Medicines and Healthcare products Regulatory Agency - MHRA (47)
Mental Health Foundation (1)
National Audit Office - NAO (2)
National Institute for Health and Care Excellence - NICE (716)
NHS England (39)
NHS Improvement (11)
NHS Providers (1)
NICE Quality and Productivity Case Studies (1)
NIHR Dissemination Centre (15)
Nuffield Trust (4)
Public Health England - PHE (41)
RAND Europe (2)
Resuscitation Council (UK) - RCUK (5)
Royal College of Obstetricians and Gynaecologists - RCOG (1)
Royal College of Paediatrics and Child Health - RCPCH (1)
Royal College of Pathologists - RCPATH (2)
Royal College of Psychiatrists - RCPsych (2)
Royal College of Speech and Language Therapists - RCSLT (1)
Royal Pharmaceutical Society (7)
Scottish Government (6)
Scottish Intercollegiate Guidelines Network - SIGN (1)
Social Care Collection (1)
Specialist Pharmacy Service (39)
US Food and Drug Administration - FDA (20)
WHO Regional Office for Europe - WHO Europe (1)

Department of Health (2)
Race Equality Foundation (0)
Faculty of Public Health - FPH (0)
FoNs Centre for Nursing Innovation (0)
Children's Brain Tumour Research Centre (0)
European Society for Medical Oncology - ESMO (0)
European Commission (1)
Scottish Medicines Consortium - SMC (26)

Date

From

To

View filters

Share
Linked In
Twitter
Facebook
Email
More...

Results for all evidence | Scottish Medicines Consortium - SMC | Medicines Current Awareness 1 - 10 of 29 sorted by relevance / date

Click export CSV or RIS to download the entire page or use the checkboxes to select a subset of records to download

Warning, download options selected.

The operation that you have selected will move away from the current results page, your download options will not persist.

Please click "Confirm" if you are happy to lose these search results.

Blocks: Tools and methodologies to assess integrated care in Europe [PDF]

Remove: European Commission source - 01 March 2017 - Publisher: European Commission

Measuring integration is different from measuring the performance of integrated care. This report addresses this dual challenge: on the one hand it focuses on design principles, building...

Read Summary

- More: Primary Research

- More: Evidence Summaries

- Remove: Quality Indicators filter
Abiraterone acetate (Zytiga®) is accepted for use within NHS Scotland

Remove: Scottish Medicines Consortium - SMC source - 13 January 2020 - Publisher: Scottish Medicines Consortium

Abiraterone acetate with prednisone or prednisolone is accepted for use in NHS Scotland for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in...

Read Summary

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
Ocrelizumab (Ocrevus®) is accepted for use within NHS Scotland

Remove: Scottish Medicines Consortium - SMC source - 13 January 2020 - Publisher: Scottish Medicines Consortium

Ocrelizumab is accepted for use within NHS Scotland for the treatment of adult patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and...

Read Summary

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
Fremanezumab (Ajovy®) is accepted for restricted use within NHS Scotland

Remove: Scottish Medicines Consortium - SMC source - 13 January 2020 - Publisher: Scottish Medicines Consortium

Fremanezumab is accepted for use in NHS Scotland for prophylaxis of migraine in adults who have at least four migraine days per month, restricted to patients with chronic and episodic migraine who...

Read Summary

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
Brentuximab vedotin (Adcetris®) is accepted for restricted use within NHS Scotland

Remove: Scottish Medicines Consortium - SMC source - 13 January 2020 - Publisher: Scottish Medicines Consortium

Brentuximab vedotin is accepted for use in NHS Scotland for adult CD30+ cutaneous T-cell lymphoma (CTCL) after one prior systemic therapy. Restricted to use in advanced CTCL (mycosis fungoides stage...

Read Summary

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
zanamivir (Dectova®) accepted for use within NHSScotland

Remove: Scottish Medicines Consortium - SMC source - 09 December 2019 - Publisher: Scottish Medicines Consortium

The SMC has accepted zanamivir for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged = 6 months) under certain...

Read Summary

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
lanadelumab (Takhzyro®) is accepted for restricted use within NHSScotland.

Remove: Scottish Medicines Consortium - SMC source - 05 December 2019 - Publisher: Scottish Medicines Consortium

Approved for routine prevention of recurrent attacks of hereditary angioedema type I or II, in patients aged =12 years, who would otherwise be considered for long-term prophylaxis with C1-esterase...

SPS comment

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
Dupilumab (Dupixent®) is accepted for restricted use within NHS Scotland

Remove: Scottish Medicines Consortium - SMC source - 13 January 2020 - Publisher: Scottish Medicines Consortium

Dupilumab is accepted for use in NHS Scotland for moderate-to-severe atopic dermatitis in adolescents (=12 to <18 years) who are candidates for systemic therapy, restricted to use in those with...

Read Summary

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
trabectedin (Yondelis®) not recommended for use within NHSScotland

Remove: Scottish Medicines Consortium - SMC source - 09 December 2019 - Publisher: Scottish Medicines Consortium

The SMC does not recommend trabectedin for the treatment of adults with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.

Read Summary

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter
lusutrombopag (Mulpleo) accepted for use within NHSScotland

Remove: Scottish Medicines Consortium - SMC source - 09 December 2019 - Publisher: Scottish Medicines Consortium

The SMC has accepted lusutrombopag for the treatment of severe thrombocytopenia in adults with chronic liver disease undergoing invasive procedures, based on data from two phase III studies.

Read Summary

- More: Prescribing and Technical Information

- Remove: Medicines Current Awareness filter

1
2
3
Next